These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 7740460)

  • 21. Serpin-resistant mutants of human tissue-type plasminogen activator.
    Madison EL; Goldsmith EJ; Gerard RD; Gething MJ; Sambrook JF
    Nature; 1989 Jun; 339(6227):721-4. PubMed ID: 2500599
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The construction and expression of chimeric urokinase-type plasminogen activator genes containing kringle domains of human plasminogen.
    Boutaud A; Castellino FJ
    Arch Biochem Biophys; 1993 Jun; 303(2):222-30. PubMed ID: 8512311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Replacement of finger and growth factor domains of tissue plasminogen activator with plasminogen kringle 1. Biochemical and pharmacological characterization of a novel chimera containing a high affinity fibrin-binding domain linked to a heterologous protein.
    Langer-Safer PR; Ahern TJ; Angus LB; Barone KM; Brenner MJ; Horgan PG; Morris GE; Stoudemire JB; Timony GA; Larsen GR
    J Biol Chem; 1991 Feb; 266(6):3715-23. PubMed ID: 1847387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel variant of t-PA resistant to plasminogen activator inhibitor-1; expression in CHO cells based on in silico experiments.
    Davami F; Sardari S; Majidzadeh-A K; Hemayatkar M; Barkhordari F; Enayati S; Adeli A; Mahboudi F
    BMB Rep; 2011 Jan; 44(1):34-9. PubMed ID: 21266104
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop.
    Dekker RJ; Eichinger A; Stoop AA; Bode W; Pannekoek H; Horrevoets AJ
    J Mol Biol; 1999 Oct; 293(3):613-27. PubMed ID: 10543954
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Development of new thrombolytic substances].
    Zeymer U; Neuhaus KL
    Herz; 1994 Dec; 19(6):314-25. PubMed ID: 7843688
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design of a novel chimeric tissue plasminogen activator with favorable Vampire bat plasminogen activator properties.
    Kazemali M; Majidzadeh-A K; Sardari S; Saadatirad AH; Khalaj V; Zarei N; Barkhordari F; Adeli A; Mahboudi F
    Enzyme Microb Technol; 2014 Dec; 67():82-6. PubMed ID: 25442953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The position of the structurally autonomous kringle 2 domain influences the functional features of tissue-type plasminogen activator.
    Bakker AH; Rehberg EF; Marotti KR; Verheijen JH
    Protein Eng; 1995 Mar; 8(3):293-300. PubMed ID: 7479691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of tryptophan-63 of the kringle 2 domain of tissue-type plasminogen activator in its thermal stability, folding, and ligand binding properties.
    Chang Y; Zajicek J; Castellino FJ
    Biochemistry; 1997 Jun; 36(25):7652-63. PubMed ID: 9201906
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and expression of a gene from kringle-2 domain of tissue plasminogen activator in E. coli.
    Hua ZC; Fu HL; Chen YH; Yu RR; Wang J; Zhu DX
    Sci China B; 1994 Jun; 37(6):667-76. PubMed ID: 7917003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression and characterization of recombinant porcine plasminogen activator inhibitor-1.
    Bijnens AP; Knockaert I; Cousin E; Kruithof EK; Declerck PJ
    Thromb Haemost; 1997 Feb; 77(2):350-6. PubMed ID: 9157595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Properties of molecular variants of tissue-type plasminogen activator.
    Krause J; Tanswell P
    Arzneimittelforschung; 1989 May; 39(5):632-7. PubMed ID: 2502992
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Construction and characterization of a t-PA mutant for use in ATTEMPTS: a drug delivery system for achieving targeted thrombolysis.
    Yang VC; Naik SS; Song H; Dombkowski AA; Crippen G; Liang JF
    J Control Release; 2005 Dec; 110(1):164-76. PubMed ID: 16260060
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator.
    Horn IR; van den Berg BM; Moestrup SK; Pannekoek H; van Zonneveld AJ
    Thromb Haemost; 1998 Nov; 80(5):822-8. PubMed ID: 9843178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Deglycosylation increases the fibrinolytic activity of a deletion mutant of tissue-type plasminogen activator.
    Wilhelm J; Kalyan NK; Lee SG; Hum WT; Rappaport R; Hung PP
    Thromb Haemost; 1990 Jun; 63(3):464-71. PubMed ID: 2119528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thrombolytic and pharmacokinetic properties of human tissue-type plasminogen activator variants, obtained by deletion and/or duplication of structural/functional domains, in a hamster pulmonary embolism model.
    Collen D; Lijnen HR; Vanlinthout I; Kieckens L; Nelles L; Stassen JM
    Thromb Haemost; 1991 Feb; 65(2):174-80. PubMed ID: 1905070
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Substitution of serine or threonine at position 473 of tissue-type plasminogen activator increases its stability in plasma.
    Alibhai M; Chow AM; Paoni NF
    Thromb Haemost; 1996 Jan; 75(1):107-12. PubMed ID: 8713788
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endocytosis of the recombinant tissue plasminogen activator alteplase by hepatic endothelial cells.
    Seydel W; Stang E; Roos N; Krause J
    Arzneimittelforschung; 1991 Feb; 41(2):182-6. PubMed ID: 1904231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Newer thrombolytic agents.
    Verstraete M
    Ann Acad Med Singap; 1999 May; 28(3):424-33. PubMed ID: 10575530
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Construction, expression and the characterization of t-PA mutants with increased plasma half-life and resistance to inhibition by PAI-1.
    Liu S; Huang P; Huang C
    Chin J Biotechnol; 1995; 11(1):17-25. PubMed ID: 7548767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.